Triptorelin
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Triptorelin: Hypertrichosis (disease)
One-Sentence Summary
Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist that suppresses sex hormone production. The TxGNN model predicts it may be useful for hypertrichosis (disease), but no clinical trials and only 1 publication were found. That publication is a case report of a drug side effect, not evidence that triptorelin treats the condition.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (6 of 6) – CDSCO approval status is not included in this data |
| Number of Listed Products | 6 (valid: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Triptorelin belongs to the GnRH agonist class. With continuous exposure, these drugs desensitise the pituitary and lower LH, FSH and sex-steroid levels. In theory, lowering androgen levels could matter for some hair-growth disorders.
In practice, the link to hypertrichosis is weak. Hypertrichosis is most often drug-induced or genetic, and it is not typically driven by gonadotropin-mediated androgen excess. No credible mechanism was identified by which triptorelin would treat it. The high model score most likely reflects proximity between the drug and the disease in the model’s data rather than a true therapeutic signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41822646 | 2026 | Case report | Cureus | Ciclosporin-induced generalised hypertrichosis in a transgender woman with psoriasis who was also taking estradiol and triptorelin. It describes a side effect of ciclosporin and does not show a benefit of triptorelin. |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 175170 | Pamorelin LA 3.75mg Injection (Dr Reddy’s Laboratories Ltd) | Vial of 1 injection | Not available |
| 175479 | Pamorelin LA 22.5mg Injection (Dr Reddy’s Laboratories Ltd) | Vial of 1 injection | Not available |
| 174365 | Pamorelin LA 11.25mg Powder for Injection (Dr Reddy’s Laboratories Ltd) | Vial of 1 powder for injection | Not available |
| 58621 | Decapeptyl 0.1mg Injection (Ferring Pharmaceuticals) | Vial of 1 ml injection | Not available |
| 59940 | Decapeptyl Depot Injection (Ferring Pharmaceuticals) | Vial of 1 injection | Not available |
All licences are for single-ingredient injectable products and are currently valid. A sixth valid licence (Tryplog Injection, Life Medicare & Biotech Pvt Ltd) is also on record.
Safety Considerations
- Drug Interactions: 262 interactions were recorded. One is rated Major: dolasetron. Many others are rated Moderate, including:
- antidiabetic drugs (acarbose, metformin, pioglitazone, glimepiride, chlorpropamide, alogliptin, saxagliptin, canagliflozin, dapagliflozin, empagliflozin, albiglutide, dulaglutide)
- clarithromycin
- famotidine
- loperamide
- palonosetron
- bowel-preparation and laxative agents (bisacodyl, picosulfuric acid, polyethylene glycol with electrolytes)
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials, and the only publication is a case report of a side effect of another drug. No plausible mechanism links GnRH agonism to treating hypertrichosis, so the evidence level is L5.
To proceed, the following is needed:
- A defined mechanistic hypothesis for how lowering sex hormones would affect hypertrichosis
- Controlled or observational clinical data on triptorelin in this condition
- Package insert warnings and contraindications for the marketed products
- Detailed mechanism-of-action data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.